{ "disease": "nasopharyngeal-carcinoma", "label": "Nasopharyngeal carcinoma", "url": "https://usebiotransfer.org/disease/nasopharyngeal-carcinoma/", "built": "2026-09-16", "facts_hash": { "answers": "68b1a2456839", "targets": "9bc7221016e7" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-16", "trials": "2026-09-16" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PDCD1", "ensembl": "ENSG00000188389", "n_drug_entries": 26, "n_distinct_drugs": 26, "drugs": { "APL-501": "PHASE_2", "BALSTILIMAB": "PHASE_3", "BUDIGALIMAB": "PHASE_2_3", "CADONILIMAB": "PHASE_3", "CAMRELIZUMAB": "PHASE_3", "CEMIPLIMAB": "APPROVAL", "CETRELIMAB": "PHASE_3", "CS-1003": "PHASE_3", "DOSTARLIMAB": "APPROVAL", "FINOTONLIMAB": "PHASE_3", "LOMVASTOMIG": "PHASE_2", "NIVOLUMAB": "APPROVAL", "PEMBROLIZUMAB": "APPROVAL", "PENPULIMAB": "PHASE_3", "PIDILIZUMAB": "PHASE_2", "PIMIVALIMAB": "PHASE_2", "PUCOTENLIMAB": "PHASE_3", "RETIFANLIMAB": "APPROVAL", "SASANLIMAB": "PHASE_3", "SERPLULIMAB": "APPROVAL", "SINTILIMAB": "APPROVAL", "SPARTALIZUMAB": "PHASE_3", "TEBOTELIMAB": "PHASE_2_3", "TISLELIZUMAB": "APPROVAL", "TORIPALIMAB": "APPROVAL", "ZIMBERELIMAB": "PHASE_3" }, "approved": [ "CEMIPLIMAB", "DOSTARLIMAB", "NIVOLUMAB", "PEMBROLIZUMAB", "RETIFANLIMAB", "SERPLULIMAB", "SINTILIMAB", "TISLELIZUMAB", "TORIPALIMAB" ], "n_approved": 9, "approved_for": { "CEMIPLIMAB": [ "squamous cell carcinoma", "basal cell carcinoma", "cutaneous squamous cell carcinoma", "cervical cancer" ], "DOSTARLIMAB": [ "endometrial cancer", "endometrial neoplasm" ], "NIVOLUMAB": [ "head and neck cancer", "pleural mesothelioma", "gastric cancer", "melanoma", "non-small cell lung carcinoma", "renal cell carcinoma", "transitional cell carcinoma", "colorectal neoplasm", "Hodgkins lymphoma", "mesothelioma", "head and neck squamous cell carcinoma", "classic Hodgkin lymphoma", "metastatic melanoma" ], "PEMBROLIZUMAB": [ "melanoma", "metastatic melanoma", "endometrium neoplasm", "head and neck squamous cell carcinoma", "transitional cell carcinoma", "renal cell carcinoma", "Hodgkins lymphoma", "non-small cell lung carcinoma" ], "RETIFANLIMAB": [ "neuroendocrine carcinoma", "Merkel cell skin cancer", "squamous cell carcinoma" ], "SERPLULIMAB": [ "esophageal squamous cell carcinoma", "non-small cell lung carcinoma", "small cell lung carcinoma" ], "SINTILIMAB": [ "Hodgkins lymphoma" ], "TISLELIZUMAB": [ "esophageal cancer", "Hodgkins lymphoma", "non-small cell lung carcinoma", "adenocarcinoma", "esophageal squamous cell carcinoma", "gastric neoplasm" ], "TORIPALIMAB": [ "melanoma", "nasopharyngeal carcinoma", "urothelial carcinoma", "esophageal squamous cell carcinoma", "Niemann-Pick disease type B" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CDKN2A", "ensembl": "ENSG00000147889", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "NFKBIA", "ensembl": "ENSG00000100906", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CYLD", "ensembl": "ENSG00000083799", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "TRAF3", "ensembl": "ENSG00000131323", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "KMT2D", "ensembl": "ENSG00000167548", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "VEGFA", "ensembl": "ENSG00000112715", "n_drug_entries": 14, "n_distinct_drugs": 13, "drugs": { "ABICIPAR PEGOL": "APPROVAL", "AFLIBERCEPT": "APPROVAL", "BEVACIZUMAB": "APPROVAL", "BEVACIZUMAB GAMMA": "APPROVAL", "BEVASIRANIB": "PHASE_3", "BROLUCIZUMAB": "APPROVAL", "CONBERCEPT": "PHASE_3", "FARICIMAB": "APPROVAL", "MUPARFOSTAT": "PHASE_3", "PEGAPTANIB": "APPROVAL", "PEGAPTANIB OCTASODIUM": "PHASE_3", "RANIBIZUMAB": "APPROVAL", "VANUCIZUMAB": "PHASE_2" }, "approved": [ "ABICIPAR PEGOL", "AFLIBERCEPT", "BEVACIZUMAB", "BEVACIZUMAB GAMMA", "BROLUCIZUMAB", "FARICIMAB", "PEGAPTANIB", "RANIBIZUMAB" ], "n_approved": 8, "approved_for": { "ABICIPAR PEGOL": [ "ocular vascular disorder" ], "AFLIBERCEPT": [ "macular degeneration", "retinal vein occlusion", "colorectal cancer", "choroidal neovascularization", "diabetic macular edema", "myopia", "edema", "metastatic colorectal cancer", "macular retinal edema", "macrovascular complications of diabetes", "wet macular degeneration", "colorectal neoplasm", "pathological myopia", "diabetic retinopathy", "colorectal adenocarcinoma", "ocular vascular disorder" ], "BEVACIZUMAB": [ "colorectal cancer", "non-small cell squamous lung carcinoma", "breast cancer", "cervical cancer", "non-small cell lung carcinoma", "colorectal adenocarcinoma", "renal cell carcinoma", "colonic neoplasm", "glioblastoma", "metastatic colorectal cancer", "breast neoplasm", "peritoneal neoplasm", "colorectal neoplasm", "fallopian tube neoplasm", "ovarian neoplasm", "fallopian tube carcinoma", "ocular vascular disorder" ], "BEVACIZUMAB GAMMA": [ "wet macular degeneration" ], "BROLUCIZUMAB": [ "macular degeneration", "wet macular degeneration", "ocular vascular disorder" ], "FARICIMAB": [ "diabetic macular edema", "wet macular degeneration", "macular retinal edema", "cystoid macular edema", "ocular vascular disorder" ], "PEGAPTANIB": [ "wet macular degeneration", "macular degeneration" ], "RANIBIZUMAB": [ "macular degeneration", "hereditary hemorrhagic telangiectasia", "macular retinal edema", "diabetic retinopathy", "wet macular degeneration", "macrovascular complications of diabetes", "myopia", "pathological myopia", "choroidal neovascularization", "retinal vein occlusion", "ocular vascular disorder" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "MTOR", "ensembl": "ENSG00000198793", "n_drug_entries": 26, "n_distinct_drugs": 25, "drugs": { "APITOLISIB": "PHASE_2", "AZD-8055": "PHASE_1_2", "BGT-226": "PHASE_1_2", "CC-115": "PHASE_2", "DACTOLISIB": "PHASE_3", "DS-3078A": "PHASE_1", "DS-7423": "PHASE_1", "GEDATOLISIB": "PHASE_3", "INDOXIMOD": "PHASE_2_3", "OMIPALISIB": "PHASE_1", "ONATASERTIB": "PHASE_2", "OSI-027": "PHASE_2", "PALOMID-529": "PHASE_1", "PANULISIB": "PHASE_1", "PERHEXILINE": "APPROVAL", "PF-04691502": "PHASE_2", "PKI-179": "PHASE_1", "RG-7603": "PHASE_1", "RIDAFOROLIMUS": "APPROVAL", "SAMOTOLISIB": "PHASE_2", "SAPANISERTIB": "PHASE_2", "SF-1126": "PHASE_2", "VISTUSERTIB": "PHASE_2", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1" }, "approved": [ "PERHEXILINE", "RIDAFOROLIMUS" ], "n_approved": 2, "approved_for": { "PERHEXILINE": [ "cardiovascular disorder", "angina pectoris" ], "RIDAFOROLIMUS": [] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] } ], "trials": { "by_antigen": { "PD-1": { "n": 235, "n_observational": 3, "n_active": 142, "n_withdrawn": 1, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03907826", "title": "PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04376866", "title": "Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04453813", "title": "Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04453826", "title": "Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04778956", "title": "Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04875611", "title": "Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment", "status": "RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944914", "title": "Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05147844", "title": "Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05290194", "title": "Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05305131", "title": "Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340491", "title": "Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628922", "title": "Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT", "status": "RECRUITING", "last_update": "2022-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652192", "title": "SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC", "status": "RECRUITING", "last_update": "2022-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05854849", "title": "Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC", "status": "RECRUITING", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05877872", "title": "Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941741", "title": "IC Plus Low-dose Radiation Plus Cadonilimab in LANPC", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06019130", "title": "Nivolumab in Children and Adults With Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064097", "title": "A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093061", "title": "Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177301", "title": "Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228079", "title": "Adjuvant vs Surgery Only in Early-stage Recurrent NPC", "status": "RECRUITING", "last_update": "2025-07-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235203", "title": "Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239727", "title": "Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06277050", "title": "Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313450", "title": "De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-03-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323239", "title": "SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06437522", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438627", "title": "Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472713", "title": "Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475300", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06636734", "title": "Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06657690", "title": "Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669611", "title": "Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676722", "title": "SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06749899", "title": "QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788002", "title": "LDRT and Chemoimmunotherapy in NPC With Liver Metastasis", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802835", "title": "EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06811844", "title": "Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851247", "title": "GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868433", "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886347", "title": "Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067268", "title": "Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154069", "title": "Adaptive Immunotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07188584", "title": "Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235319", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07258979", "title": "A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277764", "title": "Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07325539", "title": "LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328841", "title": "Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328854", "title": "40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340515", "title": "Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial", "status": "RECRUITING", "last_update": "2026-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07362979", "title": "Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392320", "title": "A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459296", "title": "Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07496190", "title": "Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528183", "title": "Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581821", "title": "Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07590024", "title": "RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625423", "title": "Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07661771", "title": "Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690787", "title": "JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07705243", "title": "Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07762976", "title": "Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07781358", "title": "Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02339558", "title": "Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2019-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605967", "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611960", "title": "Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)", "status": "COMPLETED", "last_update": "2023-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044743", "title": "PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies", "status": "UNKNOWN", "last_update": "2017-05-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097939", "title": "Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121716", "title": "A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects", "status": "COMPLETED", "last_update": "2022-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267498", "title": "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390738", "title": "Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy", "status": "WITHDRAWN", "last_update": "2021-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03427827", "title": "PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544099", "title": "Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA", "status": "TERMINATED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03558191", "title": "SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03581786", "title": "The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619824", "title": "PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03700476", "title": "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707509", "title": "Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734809", "title": "NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813394", "title": "Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854838", "title": "IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03866967", "title": "A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891953", "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924986", "title": "Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925090", "title": "Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03930498", "title": "Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03984357", "title": "Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072107", "title": "EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073784", "title": "Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143984", "title": "Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220307", "title": "A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221516", "title": "Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227509", "title": "Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282070", "title": "SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04350190", "title": "Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2023-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398056", "title": "Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405622", "title": "Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2023-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04446663", "title": "Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447326", "title": "Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517214", "title": "Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547088", "title": "Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548271", "title": "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04586088", "title": "Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04605562", "title": "Umbrella Biomarker-Guided Therapy in NPC", "status": "NOT_YET_RECRUITING", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736810", "title": "A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04769076", "title": "The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04782765", "title": "Phase \u2161 Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04825990", "title": "Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830267", "title": "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04833257", "title": "Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870905", "title": "Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895345", "title": "A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04907370", "title": "PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04910347", "title": "Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917770", "title": "The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921995", "title": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04945421", "title": "IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC", "status": "COMPLETED", "last_update": "2023-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04955886", "title": "Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974398", "title": "A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978012", "title": "Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy", "status": "UNKNOWN", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992988", "title": "Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996758", "title": "Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05011227", "title": "Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020925", "title": "SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092217", "title": "Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05097209", "title": "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128201", "title": "Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162872", "title": "Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "status": "TERMINATED", "last_update": "2025-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193617", "title": "Penpulimab Combined With GP \u00b1 Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198531", "title": "To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2022-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201859", "title": "Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211232", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222009", "title": "G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229315", "title": "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340270", "title": "PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341193", "title": "PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385926", "title": "Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417139", "title": "Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study", "status": "UNKNOWN", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431764", "title": "Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448885", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484375", "title": "Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513573", "title": "Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520814", "title": "PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial", "status": "UNKNOWN", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524168", "title": "SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05549466", "title": "Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563480", "title": "TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576272", "title": "A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05587374", "title": "Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724355", "title": "CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751486", "title": "A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05790200", "title": "Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807880", "title": "Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05813626", "title": "Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05869227", "title": "Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904080", "title": "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955105", "title": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095167", "title": "Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06118333", "title": "A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06156878", "title": "PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "UNKNOWN", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331845", "title": "Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364826", "title": "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06440187", "title": "Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11", "status": "COMPLETED", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486220", "title": "PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06490341", "title": "GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561763", "title": "TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06605131", "title": "GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06664983", "title": "TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680115", "title": "Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712888", "title": "Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752382", "title": "Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06781112", "title": "A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06987123", "title": "TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062484", "title": "A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07064902", "title": "Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07110558", "title": "Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129772", "title": "Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136519", "title": "Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07138989", "title": "EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07248696", "title": "Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07267338", "title": "Pembrolizumab + MRGOO3 as Neoadjuvant in NPC", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320963", "title": "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07331428", "title": "MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07373990", "title": "Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381699", "title": "MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388758", "title": "Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388836", "title": "Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07524413", "title": "Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540390", "title": "GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565389", "title": "Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07650266", "title": "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783321", "title": "A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07794488", "title": "Platinum-Free Regimen in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797881", "title": "A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PD-1", "toripalimab", "Loqtorzi", "camrelizumab", "tislelizumab", "pembrolizumab", "nivolumab", "penpulimab", "sintilimab" ] }, "PD-L1": { "n": 31, "n_observational": 3, "n_active": 16, "n_withdrawn": 1, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05397769", "title": "Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.", "status": "RECRUITING", "last_update": "2022-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349889", "title": "Adebrelimab and Chemoradiotherapy in High-risk LANPC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06455410", "title": "GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839066", "title": "A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07781358", "title": "Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605967", "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611960", "title": "Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)", "status": "COMPLETED", "last_update": "2023-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02875613", "title": "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891953", "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04231864", "title": "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282070", "title": "SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447612", "title": "Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895345", "title": "A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04945421", "title": "IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC", "status": "COMPLETED", "last_update": "2023-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020925", "title": "SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162872", "title": "Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198531", "title": "To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2022-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222009", "title": "G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06118333", "title": "A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06629597", "title": "A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238569", "title": "Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385079", "title": "Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "durvalumab" ] }, "EGFR": { "n": 74, "n_observational": 8, "n_active": 22, "n_withdrawn": 0, "trials": [ { "nct": "NCT05717790", "title": "Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-02-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06194656", "title": "Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676722", "title": "SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802835", "title": "EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038343", "title": "AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101744", "title": "Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07584499", "title": "Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004865", "title": "Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy", "status": "COMPLETED", "last_update": "2009-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00009841", "title": "Gene Therapy in Treating Patients With Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2016-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00015964", "title": "ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2013-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00024089", "title": "Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049283", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00083057", "title": "Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2012-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00212108", "title": "A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839", "status": "COMPLETED", "last_update": "2012-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00228488", "title": "Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma", "status": "COMPLETED", "last_update": "2007-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301028", "title": "Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524017", "title": "Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract", "status": "COMPLETED", "last_update": "2020-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629226", "title": "Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2011-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00700440", "title": "Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy", "status": "COMPLETED", "last_update": "2010-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738868", "title": "Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00891904", "title": "Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2016-04-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00906360", "title": "Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2013-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00939627", "title": "Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01074021", "title": "Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2015-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01230476", "title": "Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "TERMINATED", "last_update": "2019-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01254617", "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01256385", "title": "Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy", "status": "COMPLETED", "last_update": "2017-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271439", "title": "Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2013-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01316757", "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326559", "title": "Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2017-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "status": "COMPLETED", "last_update": "2015-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01534585", "title": "Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2018-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01540682", "title": "MLN8237 in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01614938", "title": "Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2012-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01616849", "title": "Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2015-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01637194", "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2012-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01712919", "title": "Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2014-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816984", "title": "PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02012062", "title": "Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2019-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02293356", "title": "Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-08-19", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02507154", "title": "Reactivating NK Cells in Treating Refractory Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02633176", "title": "Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025958", "title": "Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422536", "title": "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529279", "title": "CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy", "status": "UNKNOWN", "last_update": "2018-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03557112", "title": "By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC", "status": "UNKNOWN", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666221", "title": "Nimotuzumab for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708822", "title": "Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03837808", "title": "Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915132", "title": "Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223024", "title": "Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04456322", "title": "Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508816", "title": "Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05126719", "title": "A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222009", "title": "G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513573", "title": "Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06156878", "title": "PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "UNKNOWN", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06490341", "title": "GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561763", "title": "TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06892431", "title": "JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02507154", "title": "Reactivating NK Cells in Treating Refractory Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "EGFR", "nimotuzumab", "cetuximab", "gefitinib" ] }, "EBV": { "n": 86, "n_observational": 35, "n_active": 34, "n_withdrawn": 3, "trials": [ { "nct": "NCT05587543", "title": "Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628922", "title": "Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT", "status": "RECRUITING", "last_update": "2022-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05674305", "title": "Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy", "status": "RECRUITING", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06019130", "title": "Nivolumab in Children and Adults With Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093061", "title": "Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313450", "title": "De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-03-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682442", "title": "Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06870435", "title": "Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas", "status": "RECRUITING", "last_update": "2025-03-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07019870", "title": "Screening for Early Diagnosis of Nose Cancer", "status": "RECRUITING", "last_update": "2025-06-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067268", "title": "Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328841", "title": "Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328854", "title": "40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07590024", "title": "RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07762976", "title": "Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078494", "title": "Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2008-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078546", "title": "EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00181220", "title": "Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma", "status": "WITHDRAWN", "last_update": "2020-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00370890", "title": "A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy", "status": "COMPLETED", "last_update": "2022-02-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00431210", "title": "Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00515957", "title": "Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)", "status": "WITHDRAWN", "last_update": "2012-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00516087", "title": "LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)", "status": "COMPLETED", "last_update": "2017-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00589186", "title": "Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609219", "title": "T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC", "status": "COMPLETED", "last_update": "2012-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00690872", "title": "Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2009-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706316", "title": "Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00834093", "title": "A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00941538", "title": "Cluster Randomized Controlled Screening Trial for NPC", "status": "UNKNOWN", "last_update": "2023-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00953420", "title": "Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00982449", "title": "124I-FIAU Imaging in EBV and KSHV Associated Cancers", "status": "COMPLETED", "last_update": "2018-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01094405", "title": "Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy", "status": "COMPLETED", "last_update": "2021-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147991", "title": "Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer", "status": "COMPLETED", "last_update": "2012-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01341834", "title": "Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors", "status": "UNKNOWN", "last_update": "2018-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01447056", "title": "Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01449942", "title": "Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2011-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744587", "title": "Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01800071", "title": "A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2018-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02065362", "title": "TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02080416", "title": "Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors", "status": "TERMINATED", "last_update": "2016-06-10", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135042", "title": "Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02269943", "title": "Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2018-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02287311", "title": "Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02363400", "title": "A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA", "status": "TERMINATED", "last_update": "2025-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02578641", "title": "A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients", "status": "COMPLETED", "last_update": "2023-06-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02761291", "title": "Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2016-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02871518", "title": "Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2016-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874651", "title": "ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02875613", "title": "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980315", "title": "A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application", "status": "UNKNOWN", "last_update": "2016-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044743", "title": "PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies", "status": "UNKNOWN", "last_update": "2017-05-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03282617", "title": "Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2017-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529279", "title": "CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy", "status": "UNKNOWN", "last_update": "2018-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544099", "title": "Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA", "status": "TERMINATED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03648697", "title": "EBV-TCR-T\uff08YT-E001\uff09for Patients With EBV-positive Recurrent or Metastatic NPC", "status": "UNKNOWN", "last_update": "2020-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03656965", "title": "EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug", "status": "UNKNOWN", "last_update": "2018-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03668730", "title": "Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682055", "title": "Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)", "status": "TERMINATED", "last_update": "2023-08-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813394", "title": "Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923842", "title": "Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours", "status": "UNKNOWN", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925896", "title": "Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients", "status": "UNKNOWN", "last_update": "2019-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072107", "title": "EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223024", "title": "Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04231864", "title": "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04456322", "title": "Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04509726", "title": "EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925544", "title": "Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "status": "TERMINATED", "last_update": "2025-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229315", "title": "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581550", "title": "Somatostatin Receptor Imaging in NPC, EBV Related Cancers", "status": "COMPLETED", "last_update": "2025-07-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654077", "title": "EBV CAR-T Cells for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05864924", "title": "A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06097793", "title": "KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06370026", "title": "KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752473", "title": "KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07138989", "title": "EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238569", "title": "Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247201", "title": "Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07248670", "title": "Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07267338", "title": "Pembrolizumab + MRGOO3 as Neoadjuvant in NPC", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07636499", "title": "Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07692906", "title": "Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07789158", "title": "Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 14, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT05587543", "title": "Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00515957", "title": "Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)", "status": "WITHDRAWN", "last_update": "2012-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609219", "title": "T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC", "status": "COMPLETED", "last_update": "2012-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00690872", "title": "Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2009-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706316", "title": "Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00953420", "title": "Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02065362", "title": "TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980315", "title": "A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application", "status": "UNKNOWN", "last_update": "2016-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03282617", "title": "Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2017-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03648697", "title": "EBV-TCR-T\uff08YT-E001\uff09for Patients With EBV-positive Recurrent or Metastatic NPC", "status": "UNKNOWN", "last_update": "2020-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925896", "title": "Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients", "status": "UNKNOWN", "last_update": "2019-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04509726", "title": "EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654077", "title": "EBV CAR-T Cells for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247201", "title": "Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "EBV", "Epstein-Barr", "LMP1", "LMP2", "EBNA1", "EBV-specific", "EBV-CTL", "tabelecleucel" ] }, "VEGF": { "n": 62, "n_observational": 2, "n_active": 20, "n_withdrawn": 0, "trials": [ { "nct": "NCT05305131", "title": "Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05854849", "title": "Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC", "status": "RECRUITING", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055816", "title": "Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438627", "title": "Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851247", "title": "GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886347", "title": "Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581821", "title": "Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690787", "title": "JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00023959", "title": "Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055913", "title": "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281840", "title": "Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00408694", "title": "Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2018-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492089", "title": "Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01309633", "title": "Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2019-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612286", "title": "Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2014-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621880", "title": "Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2019-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02237924", "title": "Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2022-02-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250599", "title": "Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02444949", "title": "A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2020-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02590133", "title": "A Phase II Clinical Trial of Chemotherapy With or Without Endostar\u00ae Continuous Intravenous Infusion in Refractory NPC", "status": "UNKNOWN", "last_update": "2017-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636231", "title": "Endostar for Locally Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874651", "title": "ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02902432", "title": "A Trial of Endostar in Patients With Carcinoma of the Head and Neck", "status": "UNKNOWN", "last_update": "2019-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02907710", "title": "Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2016-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03130270", "title": "Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03180476", "title": "Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213587", "title": "Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)", "status": "UNKNOWN", "last_update": "2017-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03601975", "title": "Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2019-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03612219", "title": "Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639467", "title": "Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-09-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813394", "title": "Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906058", "title": "Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy", "status": "COMPLETED", "last_update": "2023-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03932266", "title": "Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2019-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073784", "title": "Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04350190", "title": "Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2023-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447326", "title": "Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547088", "title": "Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548271", "title": "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553510", "title": "Treatment of Bevacizumab Followed by Steroid in RN", "status": "UNKNOWN", "last_update": "2020-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04586088", "title": "Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736810", "title": "A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996758", "title": "Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177237", "title": "Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193617", "title": "Penpulimab Combined With GP \u00b1 Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198531", "title": "To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2022-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05232552", "title": "Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341193", "title": "PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05549466", "title": "Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807880", "title": "Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364826", "title": "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06611826", "title": "GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752382", "title": "Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07064902", "title": "Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320963", "title": "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385079", "title": "Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540390", "title": "GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07794488", "title": "Platinum-Free Regimen in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "VEGF", "bevacizumab", "apatinib", "anlotinib", "endostar" ] }, "CTLA-4": { "n": 14, "n_observational": 0, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT05941741", "title": "IC Plus Low-dose Radiation Plus Cadonilimab in LANPC", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06749899", "title": "QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097939", "title": "Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03752398", "title": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220307", "title": "A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04945421", "title": "IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC", "status": "COMPLETED", "last_update": "2023-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05587374", "title": "Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05790200", "title": "Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898256", "title": "Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904080", "title": "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06664983", "title": "TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "CTLA-4", "ipilimumab", "cadonilimab" ] } }, "by_drug": { "ADEBRELIMAB": { "n": 5, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349889", "title": "Adebrelimab and Chemoradiotherapy in High-risk LANPC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06455410", "title": "GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238569", "title": "Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02875613", "title": "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562441", "title": "NPC - AXEL Study : Axitinib-Avelumab", "status": "COMPLETED", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BEVACIZUMAB": { "n": 18, "n_observational": 1, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT05305131", "title": "Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00023959", "title": "Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055913", "title": "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281840", "title": "Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00408694", "title": "Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2018-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492089", "title": "Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01309633", "title": "Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2019-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621880", "title": "Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2019-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250599", "title": "Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813394", "title": "Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553510", "title": "Treatment of Bevacizumab Followed by Steroid in RN", "status": "UNKNOWN", "last_update": "2020-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341193", "title": "PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364826", "title": "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752382", "title": "Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BEVACIZUMAB GAMMA": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT00408694", "title": "Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2018-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04396886", "title": "Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01816984", "title": "PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113878", "title": "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CADONILIMAB": { "n": 5, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05941741", "title": "IC Plus Low-dose Radiation Plus Cadonilimab in LANPC", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05587374", "title": "Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05790200", "title": "Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898256", "title": "Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06664983", "title": "TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CAMRELIZUMAB": { "n": 37, "n_observational": 0, "n_active": 17, "n_withdrawn": 0, "trials": [ { "nct": "NCT04453826", "title": "Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944914", "title": "Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05854849", "title": "Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC", "status": "RECRUITING", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239727", "title": "Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438627", "title": "Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669611", "title": "Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06811844", "title": "Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235319", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528183", "title": "Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121716", "title": "A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects", "status": "COMPLETED", "last_update": "2022-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03427827", "title": "PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03558191", "title": "SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707509", "title": "Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143984", "title": "Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221516", "title": "Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547088", "title": "Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548271", "title": "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04586088", "title": "Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04782765", "title": "Phase \u2161 Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830267", "title": "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978012", "title": "Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy", "status": "UNKNOWN", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05011227", "title": "Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05097209", "title": "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128201", "title": "Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431764", "title": "Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524168", "title": "SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05549466", "title": "Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576272", "title": "A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724355", "title": "CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07794488", "title": "Platinum-Free Regimen in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEMIPLIMAB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06980038", "title": "Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07650266", "title": "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 32, "n_observational": 4, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06194656", "title": "Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004865", "title": "Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy", "status": "COMPLETED", "last_update": "2009-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301028", "title": "Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524017", "title": "Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract", "status": "COMPLETED", "last_update": "2020-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629226", "title": "Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2011-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00700440", "title": "Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy", "status": "COMPLETED", "last_update": "2010-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738868", "title": "Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00891904", "title": "Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2016-04-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00906360", "title": "Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2013-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00939627", "title": "Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01230476", "title": "Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "TERMINATED", "last_update": "2019-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01254617", "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01256385", "title": "Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy", "status": "COMPLETED", "last_update": "2017-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271439", "title": "Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2013-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01316757", "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326559", "title": "Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2017-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "status": "COMPLETED", "last_update": "2015-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01540682", "title": "MLN8237 in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01614938", "title": "Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2012-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01637194", "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2012-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01712919", "title": "Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2014-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816984", "title": "PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02507154", "title": "Reactivating NK Cells in Treating Refractory Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02633176", "title": "Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422536", "title": "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529279", "title": "CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy", "status": "UNKNOWN", "last_update": "2018-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508816", "title": "Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003257", "title": "Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2013-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT04231864", "title": "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447612", "title": "Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05397769", "title": "Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.", "status": "RECRUITING", "last_update": "2022-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055816", "title": "Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06059261", "title": "Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 15, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030576", "title": "Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049283", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055770", "title": "Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055913", "title": "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00063895", "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079053", "title": "Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281866", "title": "Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410826", "title": "Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00603915", "title": "A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2019-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "status": "TERMINATED", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01316757", "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEFITINIB": { "n": 6, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00015964", "title": "ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2013-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00024089", "title": "Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00083057", "title": "Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2012-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00212108", "title": "A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839", "status": "COMPLETED", "last_update": "2012-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00228488", "title": "Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma", "status": "COMPLETED", "last_update": "2007-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ICOTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01534585", "title": "Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2018-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02328261", "title": "A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00098631", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114283", "title": "Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00098631", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114283", "title": "Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 25, "n_observational": 0, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT05717790", "title": "Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-02-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676722", "title": "SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101744", "title": "Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01074021", "title": "Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2015-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01616849", "title": "Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2015-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02012062", "title": "Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2019-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02293356", "title": "Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-08-19", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025958", "title": "Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03557112", "title": "By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC", "status": "UNKNOWN", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666221", "title": "Nimotuzumab for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708822", "title": "Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03837808", "title": "Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915132", "title": "Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223024", "title": "Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04456322", "title": "Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508816", "title": "Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06490341", "title": "GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561763", "title": "TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "NIVOLUMAB": { "n": 16, "n_observational": 0, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT04875611", "title": "Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment", "status": "RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06019130", "title": "Nivolumab in Children and Adults With Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064097", "title": "A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02339558", "title": "Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2019-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097939", "title": "Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267498", "title": "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390738", "title": "Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy", "status": "WITHDRAWN", "last_update": "2021-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03984357", "title": "Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04910347", "title": "Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904080", "title": "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06440187", "title": "Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11", "status": "COMPLETED", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561763", "title": "TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "PEMBROLIZUMAB": { "n": 25, "n_observational": 0, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05305131", "title": "Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06636734", "title": "Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868433", "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611960", "title": "Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)", "status": "COMPLETED", "last_update": "2023-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544099", "title": "Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA", "status": "TERMINATED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734809", "title": "NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813394", "title": "Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227509", "title": "Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04825990", "title": "Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "status": "TERMINATED", "last_update": "2025-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129772", "title": "Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07267338", "title": "Pembrolizumab + MRGOO3 as Neoadjuvant in NPC", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PENPULIMAB": { "n": 8, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06788002", "title": "LDRT and Chemoimmunotherapy in NPC With Liver Metastasis", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886347", "title": "Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392320", "title": "A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736810", "title": "A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974398", "title": "A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193617", "title": "Penpulimab Combined With GP \u00b1 Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563480", "title": "TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807880", "title": "Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PUCOTENLIMAB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06976190", "title": "A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381699", "title": "MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07524413", "title": "Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SERPLULIMAB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05513573", "title": "Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177443", "title": "Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SINTILIMAB": { "n": 18, "n_observational": 1, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT07459296", "title": "Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581821", "title": "Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619824", "title": "PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03700476", "title": "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072107", "title": "EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04769076", "title": "The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917770", "title": "The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04945421", "title": "IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC", "status": "COMPLETED", "last_update": "2023-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162872", "title": "Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201859", "title": "Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417139", "title": "Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study", "status": "UNKNOWN", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364826", "title": "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06490341", "title": "GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680115", "title": "Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752382", "title": "Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SPARTALIZUMAB": { "n": 21, "n_observational": 0, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT04778956", "title": "Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06437522", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475300", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802835", "title": "EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392320", "title": "A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07705243", "title": "Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605967", "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619824", "title": "PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03700476", "title": "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891953", "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830267", "title": "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092217", "title": "Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05097209", "title": "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201859", "title": "Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783321", "title": "A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797881", "title": "A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISLELIZUMAB": { "n": 28, "n_observational": 1, "n_active": 21, "n_withdrawn": 0, "trials": [ { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652192", "title": "SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC", "status": "RECRUITING", "last_update": "2022-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093061", "title": "Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177301", "title": "Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472713", "title": "Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676722", "title": "SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067268", "title": "Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235319", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328854", "title": "40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528183", "title": "Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07762976", "title": "Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924986", "title": "Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04833257", "title": "Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870905", "title": "Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921995", "title": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211232", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448885", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331845", "title": "Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06781112", "title": "A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07248696", "title": "Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07331428", "title": "MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07373990", "title": "Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388758", "title": "Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TORIPALIMAB": { "n": 69, "n_observational": 0, "n_active": 50, "n_withdrawn": 0, "trials": [ { "nct": "NCT03907826", "title": "PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04376866", "title": "Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04453813", "title": "Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04778956", "title": "Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05147844", "title": "Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340491", "title": "Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628922", "title": "Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT", "status": "RECRUITING", "last_update": "2022-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05877872", "title": "Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228079", "title": "Adjuvant vs Surgery Only in Early-stage Recurrent NPC", "status": "RECRUITING", "last_update": "2025-07-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235203", "title": "Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06277050", "title": "Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313450", "title": "De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-03-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323239", "title": "SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472713", "title": "Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851247", "title": "GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154069", "title": "Adaptive Immunotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235319", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07258979", "title": "A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07325539", "title": "LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328841", "title": "Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340515", "title": "Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial", "status": "RECRUITING", "last_update": "2026-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07362979", "title": "Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528183", "title": "Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625423", "title": "Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03581786", "title": "The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854838", "title": "IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925090", "title": "Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03930498", "title": "Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073784", "title": "Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398056", "title": "Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405622", "title": "Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2023-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04446663", "title": "Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447326", "title": "Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517214", "title": "Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04907370", "title": "PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04955886", "title": "Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992988", "title": "Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996758", "title": "Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229315", "title": "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341193", "title": "PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484375", "title": "Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751486", "title": "A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05813626", "title": "Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05869227", "title": "Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955105", "title": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561763", "title": "TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06605131", "title": "GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712888", "title": "Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06987123", "title": "TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07110558", "title": "Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136519", "title": "Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320963", "title": "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388836", "title": "Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540390", "title": "GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00937417", "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }